SLS
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance
Article Summary
HOLD- Sellas Life Sciences (NASDAQ: SLS) rose 0.3% overnight after CEO Angelos Stergiou's latest update sent retail investors dissecting every line for potential buyout clues, with references to quiet period and database lock reigniting takeover speculation ahead of Friday appearance on Fox & Friends.
- SELLAS Life Sciences Group has entered a quiet period regarding specific clinical updates, meaning he will not discuss study-specific details while focusing on operational execution, preparing for database lock, advancing BLA/CTD regulatory work, and driving the SLS009 program forward, with Regal nearing 80th event in pivotal Phase 3 GPS trial evaluating galinpepimut-S in acute myeloid leukemia reaching 78 of 80 events needed to trigger final analysis.
- Sellas has said it will announce 80thevent before entering formal quiet period until topline data, with CEO pushing back against claims that slower event rate signals stronger survival in either trial arm, reminding investors that Sellas remains blinded.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 120.4% | 20% | 100.0 ptsMassive Upside (120.4%) - Target: $27.50 vs Current: $12.48 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -21.4% | 15% | 40.0 ptsMild Pullback (-21.4%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SLS
- SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
- The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
- SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.